



Announcement Summary

Entity name
RADIOPHARM THERANOSTICS LIMITED

Announcement Type
New announcement

Date of this announcement
Thursday December 19, 2024

The +securities to be quoted are:
Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

In connection to NanoMab's development milestone being met and paid in shares as previously detailed in the IPO prospectus dated 23 Nov 2021. For further details refer to page 79 and 80 in the prospectus document (Link: <https://announcements.asx.com.au/asxpdf/20211123/pdf/4539r3nqcy0t7y.pdf>).

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
RAD	ORDINARY FULLY PAID	20,594,438	13/12/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

RADIOPHARM THERANOSTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

647877889

1.3 ASX issuer code

RAD

1.4 The announcement is

New announcement

1.5 Date of this announcement

19/12/2024



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

In connection to NanoMab's development milestone being met and paid in shares as previously detailed in the IPO prospectus dated 23 Nov 2021. For further details refer to page 79 and 80 in the prospectus document (Link: <https://announcements.asx.com.au/asxpdf/20211123/pdf/4539r3nqcy0t7y.pdf>).

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

RAD : ORDINARY FULLY PAID

Issue date

13/12/2024

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

20,594,438

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

In connection to NanoMab's development milestone being met and paid in shares as previously detailed in the IPO prospectus dated 23 Nov 2021.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.036000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

In connection to NanoMab's development milestone being met and paid in shares as previously detailed in the IPO prospectus dated 23 Nov 2021.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
RADO : OPTION EXPIRING 30-NOV-2026	79,352,040
RAD : ORDINARY FULLY PAID	2,193,555,194
RADOA : OPTION EXPIRING 24-AUG-2026	818,890,534

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
RADAK : OPTION EXPIRING 01-JUN-2027 EX \$0.60	2,500,000
RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED	5,700,006
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	72,262,387
RADAJ : OPTION EXPIRING 01-JUL-2027 EX \$0.17	13,137,976
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED	8,666,678
RADAG : OPTION EXPIRING 25-NOV-2026 EX \$0.60	5,066,672
RADAH : OPTION EXPIRING 22-DEC-2025 EX \$0.60	400,000
RADAI : OPTION EXPIRING 27-MAY-2027 EX \$0.60	740,000
RADAP : OPTION EXPIRING 24-APR-2028 EX \$0.09	8,955,224
RADAAA : OPTION EXPIRING 24-FEB-2025 EX \$0.05	149,925,040



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

16